Cancer medicine is in the early phase of an unprecedented shift toward personalized oncology-tailoring treatment more precisely, based on the molecular profile of an individual's disease. The goal of precision oncology is to achieve better efficacy and less toxicity, bringing to bear the entire spectrum of available diagnostic and therapeutic tools and knowledge to target what may be most relevant and effective for each individual patient -each "n of one."
Relying on the traditional cancer care approach to deliver precision oncology diagnosis and treatment is extremely time- and cost-intensive, requiring care providers to identify, access, and coordinate for each patient the latest relevant molecular diagnostic tests, assimilate and manage vast amounts of increasingly complex data, keep current on fast-moving research advances and clinical trials, and understand the latest in novel cancer treatments-while ensuring that these steps are executed as reliably, efficiently, and cost-effectively as possible.
N-of-One launched in 2008 to streamline the evaluation, synthesis, and management of the sophisticated mix of molecular-targeted tools and knowledge in the fast-moving, data-intensive realm of cancer research, diagnostics, and treatment. N-of-One links precise data on each patient's tumor molecular profile with the latest tools, knowledge, and therapeutic approaches in a single integrated platform, PrecisionWorks.
Powered by PrecisionWorks, N-of-One generates reports that help physicians and patients identify optimal diagnostic and treatment strategies. In addition, our platform powers a unified knowledge network across the precision medicine care continuum-linking next-generation sequencing technologies, large and small molecular diagnostic and genetic test companies, research laboratories, ongoing research advances and clinical trials-to optimize point-of-diagnosis through point-of-care decisions and productivity for every patient.
- Oncologists and cancer patients use N-of-One to develop optimal personalized medicine strategies
- Diagnostic companies use N-of-One to ensure the targeted use of their molecular-based tests at the point of care
- Healthcare payers use N-of-One to ensure high-quality treatment outcomes and cost-effective care
- Drug and technology innovators use N-of-One to improve the process and economics of their development programs